Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.48 USD
Change Today -0.11 / -2.40%
Volume 555.7K
OSUR On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

orasure technologies inc (OSUR) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/22/14 - $10.93
52 Week Low
09/30/15 - $4.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

orasure technologies inc (OSUR) Related Businessweek News

No Related Businessweek News Found

orasure technologies inc (OSUR) Details

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its primary products include OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepIT—MAX, OMNIgene—Gut, OMNIgene Sputum, Intercept, MICRO-PLATE DOA Assays, Intercept i2, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company manufactures and sells oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, it provides medical devices used for the removal of benign skin lesions by cryosurgery or freezing; various immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

320 Employees
Last Reported Date: 03/12/15
Founded in 1979

orasure technologies inc (OSUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.1K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $455.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $327.6K
Principal Accounting Officer, Senior Vice Pre...
Total Annual Compensation: $261.8K
Executive Vice President of Marketing and Sal...
Total Annual Compensation: $375.8K
Compensation as of Fiscal Year 2014.

orasure technologies inc (OSUR) Key Developments

OraSure Technologies, Inc. Provides Update on OraQuick Ebola Rapid Antigen Test Business

OraSure Technologies, Inc. announced that it has made significant progress regarding the commercialization of its OraQuick Ebola Rapid Antigen Test. The company announced that the Biomedical Advanced Research Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) has exercised an option to provide $7.2 million in additional funding for the Company's OraQuick Ebola Rapid Antigen Test. This funding will be used primarily for clinical and regulatory activities required to request U.S. Food and Drug Administration (FDA) 510(k) clearance for this product. This option is part of the $10.4 million funding contract (base plus options) between OraSure and BARDA that was previously announced in June 2015. The company also announced that HHS' Centers for Disease Control and Prevention (CDC) will purchase approximately $1.5 million of the Company's OraQuick Ebola Rapid Antigen Test. The CDC purchase is expected to be fulfilled by the end of 2015. CDC is purchasing the OraQuick Ebola Rapid Antigen Tests for field testing in West Africa. This is the second such purchase of this product for field testing made by CDC. The OraQuick Ebola Rapid Antigen Test utilizes the same proven technology platform used in the company's rapid HIV and HCV test kits. The OraQuick Ebola Test received Emergency Use Authorization (EUA) from the FDA in July 2015 and is designed to detect viral antigens in fingerstick and venous whole blood from patients presenting with signs and symptoms of Ebola infection in conjunction with epidemiological risk factors. Positive (reactive) results may be read as soon as they appear and have been observed as early as 4 minutes. Negative (non-reactive) results have to be read at 30 minutes. The test can be used at ambient temperatures (up to 40°C /104°F), is easy to use with a simple visual read, and does not require instrumentation.

OraSure Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter of 2015

OraSure Technologies Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenues of USD 30,388,000 against USD 26,401,000 a year ago. Operating income was USD 2,721,000 against USD 2,497,000 a year ago. Income before income tax was USD 2,626,000 against USD 2,355,000 a year ago. Net income was USD 2,968,000 or USD 0.03 per basic and diluted share compared USD 2,529,000 or USD 0.04 per diluted share a year ago. For the six months period, the company reported net revenues of USD 57,476,000 against USD 49,938,000 a year ago. Operating income was USD 2,430,000 against operating loss of USD 3,121,000 a year ago. Income before income tax was USD 2,744,000 against loss before income tax of USD 3,145,000 a year ago. Net income was USD 2,081,000 or USD 0.04 per basic and diluted share compared net loss of USD 3,102,000 or USD 0.06 per basic and diluted share a year ago. Capital expenditures were USD 1,145,000 compared to USD 1,988,000 a year ago. Cash used in operating activities was USD 3,421,000 compared to USD 10,397,000 a year ago. For the third quarter of 2015, on consolidated basis, the company is projecting net revenues of approximately USD 29.5 to USD 30.0 million. Bottom line performance of approximately breakeven to a net loss of USD 0.01 per share, primarily due to significantly higher costs expected under HCV co-promotion agreement coupled with the lower consolidated revenues.

OraSure Technologies, Inc. to Report Q2, 2015 Results on Aug 05, 2015

OraSure Technologies, Inc. announced that they will report Q2, 2015 results at 4:00 PM, US Eastern Standard Time on Aug 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSUR:US $4.48 USD -0.11

OSUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akers Biosciences Inc $3.50 USD +0.10
Chembio Diagnostics Inc $4.48 USD +0.12
MedMira Inc C$0.04 CAD 0.00
Nymox Pharmaceutical Corp $3.67 USD +0.24
Pernix Therapeutics Holdings Inc $3.11 USD -0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation OSUR Industry Range
Price/Earnings 100.0x
Price/Sales 2.3x
Price/Book 1.7x
Price/Cash Flow 467.5x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORASURE TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at